“We do expect it to step down again. Just makes sense. That will be the fourth full year.”

In context

“sform IBD, we remain very confident. It's not a zero sum game. We feel very confident in our profile and what we're able to deliver if we look across UC, if we look across our head to head data versus sequence versus the other trials. And so net net, we see very, very strong momentum across the board, regardless of competitors that may come in. And then my thoughts on the Humira tail. Again, as I highlighted and Scott highlighted in his remarks, we are seeing a bit of faster erosions as the biosimilar start to play out. And this is, of course, the third year of the biosimilar event. So it's really not too surprising. We also do continue to see the molecule continue to erode. So as we look and we don't have full visibility and we'll be monitoring the 26 access as we go throughout the year. We do expect it to step down again. Just makes sense. That will be the fourth full year. So we'll have deeper visibility of that tail sometime over the course of the year. But as we said before, the real impact of the tail is when Humira does not have a meaningful headwind to our overall growth as a corporation. So we expect that to start to develop over that ’26 time period. Okay. Operator: Next we'll go to the line of Terence Flynn from Morgan Stanley. Please go ahead. Terence Flynn: Great. Thanks so much. Congrats on the quarter. And maybe two questions for me as well. You alluded to some of the mitigation strategies you're taking with respect to tariffs potentially. Could you just elaborate a little bit more there in terms of what that means for maybe inventory and then any contemplation on any changes to IP domiciling? And the second question I had is on the amylin progr”